Australia's Next Science rises on positive FY24 forecast

Next Science

03/05/2024 04:28

** Shares of medical technology co Next Science  NXS.AX 
rise as much as 3.1% to A$0.33
    ** Co says it remains focused on achieving revenue of $36
mln-$40 mln in FY24 and expects to be EBITDA and cash flow
positive during H2 FY24
    ** Says immediate priorities for FY24 are to deliver
significant topline growth across its three key areas
    ** At current levels, stock trims YTD declines to 2.9% from
5.9% at last close

 (Reporting by Megha Rani in Bengaluru)
 ((Megha.Rani2@thomsonreuters.com;))